Trabectedin - Johnson & Johnson/University of Illinois
Alternative Names: Ecteinascidin; Ecteinascidin-743; ET-743; NSC-684766; YondelisLatest Information Update: 22 Jun 2024
At a glance
- Originator University of Illinois
- Developer Bristol-Myers Squibb; European Organisation for Research and Treatment of Cancer; Johnson & Johnson; Mario Negri Institute for Pharmacological Research; National Cancer Institute (USA); PharmaMar; Taiho Pharmaceutical
- Class Antineoplastics; Dioxoles; Small molecules; Tetrahydroisoquinolines
- Mechanism of Action Alkylating agents; DNA synthesis inhibitors; Macrophage inhibitors; P-glycoprotein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Ovarian cancer; Soft tissue sarcoma
- Phase III Fallopian tube cancer; Peritoneal cancer
- Phase II Leiomyosarcoma; Liposarcoma; Malignant-mesothelioma; Meningioma; Non-small cell lung cancer; Solid tumours
- No development reported Breast cancer; Prostate cancer
Most Recent Events
- 07 Apr 2024 Pharmacodynamics data from a preclinical study in bone cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 28 Feb 2024 No recent reports of development identified for phase-I development in Ovarian-cancer(Combination therapy, Late-stage disease) in Japan (IV, Infusion)
- 19 Dec 2023 National Center for Tumor Diseases, Heidelberg collaboration with AstraZeneca and PharmaMar completes a (phase) trial in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Recurrent, Second-line therapy or greater) in Germany (IV) (EudraCT2017-001755-31) (NCT03127215)